Cara Therapeutics reported $176.17M in Current Assets for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Acadia Pharmaceuticals ACAD:US $ 532.52M 9.7M
Acelrx Pharmaceuticals ACRX:US $ 42.81M 12.68M
Aerie Pharmaceuticals AERI:US $ 311.41M 5.56M
Cara Therapeutics CARA:US $ 176.17M 24.4M
Chugai Pharma 4519:JP Y 1126523M 34875M
Depomed DEPO:US $ 117.39M 7.73M
Endo International Ordinary Shares ENDP:US $ 2492.79M 221.79M
Halozyme Therapeutics HALO:US $ 988.69M 62.4M
Horizon Pharma HZNP:US $ 3203.09M 255.36M
JAZZ PHA JAZZ:US $ 2590.83M 89.98M
Neurocrine Biosciences NBIX:US $ 1019.3M 1.1M
Pacira Pharmaceuticals PCRX:US $ 526.21M 140.81M
Pain Therapeutics PTIE:US $ 204.2M 18M
Redhill Biopharma RDHL:US $ 72.58M 16.58M
Revance Therapeutics RVNC:US $ 285.33M 39.21M
Supernus Pharmaceuticals SUPN:US $ 625.12M 56.6M
Teva Pharmaceutical Industries TEVA:US $ 12164M 287M
Vanda Pharmaceuticals VNDA:US $ 496.9M 4.63M